Ensituximab

Drug Profile

Ensituximab

Alternative Names: NEO-101; NEO-102; NPC-1C

Latest Information Update: 09 Feb 2016

Price : $50

At a glance

  • Originator Neogenix Oncology
  • Developer Duke University Medical Center; H. Lee Moffitt Cancer Center and Research Institute; Johns Hopkins Medical Institutions; Montefiore Medical Center; National Cancer Institute (USA); Precision Biologics; University of North Carolina; University of Texas Southwestern Medical Center; Yale University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Neoplasm antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 09 Feb 2016 Updated efficacy data from a phase II trial in Colorectal cancer released by Precision Biologics
  • 25 Sep 2015 Ensituximab is still in phase I/II trials for Pancreatic cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in the USA
  • 23 May 2015 Efficacy and adverse event data from a phase II trial in Colorectal cancer released by Precision Biologics ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top